This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hagemeijer, F. Search for Related Content PubMed PubMed Citation Articles by Hagemeijer, F.

Circulation, Vol 57, 751-755, Copyright © 1978 by American Heart Association

ARTICLES

Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction

F Hagemeijer

In 16 patients, a sustained supraventricular tachyarrhythmia occurring less than 72 hours after the first symptom of an acute myocardial infarction was treated with titrated doses of verapamil. The drug was given intravenously in 1 mg increments every minute under continuous monitoring of electrocardiogram and blood pressure. Endpoints for the administration of verapamil were the following: reversion to sinus rhythm; a ventricular rate slower than 100/min; hypotension; a pulmonary capillary wedge pressure rising above 15 mm Hg; signs of intolerance; a maximum dose of 20 mg. Reversion to sinus rhythm was observed in 7/8 patients in atrial flutter and in 1/8 patients in atrial fibrillation; in all the ventricular rate could be slowed below 100/min without untoward effects.

This article has been cited by other articles:

				A. E. Skolnick and W. H. Frishman Calcium Channel Blockers in Myocardial Infarction Arch Intern Med, July 1, 1989; 149(7): 1669 - 1677. [Abstract] [PDF]

				M. H. Hwang, J. Danoviz, I. Pacold, N. Rad, H. S. Loeb, and R. M. Gunnar Double-blind Crossover Randomized Trial of Intravenously Administered Verapamil: Its Use for Atrial Fibrillation and Flutter Following Open Heart Surgery Arch Intern Med, March 1, 1984; 144(3): 491 - 494. [Abstract] [PDF]

				C. Tommaso, T. McDonough, M. Parker, and J. V. Talano Atrial Fibrillation and Flutter: Immediate Control and Conversion With Intravenously Administered Verapamil Arch Intern Med, May 1, 1983; 143(5): 877 - 881. [Abstract] [PDF]

				B. N. Singh Pharmacological Basis for the Therapeutic Applications of Slow-Channel Blocking Drugs Angiology, August 1, 1982; 33(8): 492 - 515. [PDF]

				J. A. Abbott Intravenous Antiarrhythmic Drugs: Newer Aspects of Therapy Angiology, April 1, 1982; 33(4): 251 - 258. [PDF]

				H. L. WAXMAN, R. J. MYERBURG, R. APPEL, and R. J. SUNG Verapamil for Control of Ventricular Rate in Paroxysmal Supraventricular Tachycardia and Atrial Fibrillation or Flutter: A Double-Blind Randomized Cross-Over Study Ann Intern Med, January 1, 1981; 94(1): 1 - 6. [Abstract] [PDF]

				E. M. ANTMAN, P. H. STONE, J. E. MULLER, and E. BRAUNWALD Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part I: Basic and Clinical Electrophysiologic Effects Ann Intern Med, December 1, 1980; 93(6): 875 - 885. [Abstract] [PDF]

				R. J. SUNG, B. ELSER, and R. G. McALLISTER Jr Intravenous Verapamil for Termination of Re-Entrant Supraventricular Tachycardias: Intracardiac Studies Correlated with Plasma Verapamil Concentrations Ann Intern Med, November 1, 1980; 93(5): 682 - 689. [Abstract] [PDF]